(PRESS RELEASE) PHOENIX — Three scientific papers regarding RevitalVision — a global leader in non-invasive vision enhancement therapies—were recently recognized with first-place honors at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The award-winning research highlights the effectiveness of RevitalVision’s technology in improving vision in patients with keratoconus and in post cataract surgery with multifocal IOL implants, underscoring a growing clinical interest in leveraging new, digital-based vision enhancement therapies as a complement to traditional treatment methods.
Findings from a randomized controlled study, Visual Perceptual Learning Improves Visual Acuity in Stable Keratoconus Patients – Preliminary Results, presented by Adi Einan-Lifshitz, MD, demonstrates that targeted, cortical stimulation can significantly enhance patients’ visual acuity and contrast sensitivity, offering a non-invasive, therapeutic way grounded in neuroplasticity. On average, patients gained an improvement of 2.4 lines in the ETDRS chart following treatment, while contrast sensitivity improved by more than 100%.
The second and third papers were presented by Lionel Raj, MD, PhD, reinforcing his reputation for clinical excellence and advances in non-invasive solutions for modern ophthalmology.
Patient-Specific Perceptual Visual Stimulation Improves Vision and Contrast Sensitivty in Crosslinked Stable Keratoconus evaluated the efficacy of RevitalVision in improving vision and contrast sensitivity in crosslinked stable keratoconus patients. The results indicate a 2.5 line improvement in visual acuity and a 100% improvement in contrast sensitivity, suggesting that visual perceptual therapy trains the brain to see better through improved image processing and can be considered as a post-operative, non-risk therapeutic adjuvant.
The third study, Cortical Stimulation Using Gabor Patches Improves Vision and Contrast Sensitivity in Dissatisfied Patients with MF-IOLS: Resutls of RCT, evaluated patients who were dissatisfied after multifocal IOL implantations. The average improvement after treatment was 2.5 lines in LogMar, and 83% improvement in contrast sensitivity.
“These latest honors reflect clinical validation of RevitalVision’s technology and its growing potential to address patients’ unmet needs,” said Charles Morris, General Manager, North America, RevitalVision. “The research highlights opportunities for eye care professionals to incorporate evidence-based, neuroplasticity-driven therapies into practice, addressing longstanding gaps in post-operative care and functional vision rehabilitation.”
Advertisement
RevitalVision’s personalized, software-based approach to perceptual learning is the only FDA-cleared product for amblyopia beyond childhood ages nine and older. The prescribed, home-based vision training software gives eye care professionals a unique tool to improve vision in diverse conditions including amblyopia, keratoconus, nystagmus, and early presbyopia by focusing on personalized cortical visual stimulation. For more information, please visit www.revitalvision.com.
